Trading in Bioretec Ltd shares commenced today on Nasdaq First North Growth Market Finland
Bioretec Ltd Company Release 28 September 2021 at 5:10 p.m. EEST
"We are extremely happy being able to offer an opportunity to our existing shareholders as well as to the investors interested in our company and our future shareholders, to trade our shares in First North Growth Market marketplace. We feel that listing our shares into public markets increases the general interest and branding of our company, which on the other hand shall support us in achieving our future targets. We strongly believe that our products can offer significant benefits to patients, healthcare and societies globally - as well as to our shareholders," says Timo Lehtonen, CEO of Bioretec Ltd.
Timo Lehtonen, CEO, tel. +358 50 433 8493
Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132
Bioretec’s mission is to promote healing after trauma or orthopedic surgery, building on a unique understanding of bioresorbable medical implants that act as scaffolds for tissue growth and eliminate the need for removal surgery of the implants. Bioretec's bioresorbable polymer implants are used worldwide and the Company intends to launch a new series of innovative implants based on a unique bioresorbable metallic alloy, RemeOsTM. The RemeOsTM product line is designed to meet the unmet medical need of demanding load-bearing fixations, and to facilitate a seamless transition for surgeons from conventional titanium implants. Better healing – Better life.
